Kornimate/medical-research-clean huggingface dataset:
mulberry syrup on oral mucositis healing

Conditions: Oral Mucositis

Summary: objective: this study was carried out to investigate the effectiveness of oral care with black mulberry syrup on oral mucositis healing in individuals with copd. study design: the quantitative part of the study was conducted as a randomized controlled experimental study, the qualitative section was conducted by in-depth interview method. the study was performed with 40 patients who were hospitalized in the chest diseases clinic. in addition to the standard practice of the clinic, the individuals in the intervention group gargled with 5 ml black mulberry syrup and waited average one minute and then swallow it. they did this application 3 times a day after meals. 10 individuals in the intervention group were interviewed by using a semi-structured interview form.

objective: this mix study was carried out to investigate the effectiveness of oral care with black mulberry syrup on oral mucositis healing in individuals with copd. study design: the quantitative part of the study was conducted as a randomized controlled experimental study, the qualitative section was conducted by in-depth interview method. approval from the ethics committee and written permission from the institution were obtained. after the participants were informed about the purpose of the study, their written consents were obtained. the study was performed with 40 patients who were hospitalized in the chest diseases clinic. in addition to the standard practice of the clinic, the individuals in the intervention group gargled with 5 ml black mulberry syrup and waited average one minute and then swallow it. they did this application 3 times a day after meals. 10 individuals in the intervention group were interviewed by using a semi-structured interview form.

Eligibility criteria:
inclusion criteria: * over 18 years of age, * no visual or hearing problem, * unimpaired time and place orientation, * no psychiatric disorders, * diagnosed with copd, * oral mucositis developed, * used nystatin and/or benzidamine hydrochloride therapy exclusion criteria: -

Keywords: oral mucositis in copd patients complementary therapies nursing interventions oral care with black mulberry syrup
dose comparison study of menactra® in us children

Conditions: Meningitis; Meningococcal Infection; Neisseria Meningitidis

Summary: to explore the potential benefit of the administration of menactra vaccine as a two-dose regimen to children. primary objective: to assess, by age group, the immune response to menactra vaccine after each vaccine injection.

this is an open-label trial designed to explore the immune response to a two-dose schedule of menactra vaccine compared with a standard one-dose schedule in children.

Eligibility criteria:
inclusion criteria : * aged 2 to \< 11 years on the day of inclusion. * provision of assent form signed by the subject (depending on age) and informed consent form signed by the parent(s) or another legally acceptable representative. * subject and parent/legal guardian able to attend all scheduled visits and comply with all trial procedures. exclusion criteria : * previous vaccination against meningococcal disease with either the trial vaccine or another vaccine. * participation in the active (i.e., treatment) portion of another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination. * planned participation in another clinical trial during the present trial period. * known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy. * suspected or known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a product containing any of the substances present in the study vaccine . * chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the investigator. * receipt of blood or blood-derived products in the past 3 months. * received any vaccine (other than desensitization therapy for allergies or influenza vaccine within 2 weeks before vaccination) in the 4 weeks preceding the first trial vaccination. * planned receipt of any vaccine within the 4 weeks following any trial vaccination(s). * known human immunodeficiency virus (hiv), hepatitis b surface antigen (hbs antigen), or hepatitis c seropositivity. * history of invasive meningococcal infection (confirmed either clinically, serologically, or microbiologically). * thrombocytopenia, coagulation disorder, or anticoagulant use in the 3 weeks preceding inclusion contraindicating intramuscular (im) vaccination. * anticipated to receive oral or injected antibiotic therapy within the 72 hours prior to any of the trial blood draws. * personal or family history of guillain-barré syndrome (gbs). * any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine.

Keywords: meningitis; meningococcal infection, neisseria meningitidis
quantitative microvasculature imaging for breast cancer detection and monitoring

Conditions: Breast Carcinoma; Breast Neoplasm

Summary: this study evaluates the effectiveness of a breast ultrasound method for the diagnosis of breast cancer. diagnostic procedures, such as breast ultrasound, may help find and diagnose breast cancer, and may help measure a patient's response to earlier treatment. the purpose of this research is to test the effectiveness of a new investigational breast ultrasound method to detect an abnormality in the breast, and assess response to breast cancer treatment.

primary objectives: i. determine the diagnostic performance of the proposed method in a population of pre-biopsy patients with suspicious breast masses and correlate the proposed method results with pathology as the gold standard. ii. assess and predict the response to preoperative chemotherapy and/or endocrine therapy in breast cancer patients using the proposed method and compare the results to magnetic resonance imaging (mri) as control and surgical pathology for pathological complete response (pcr). iii. determine the diagnostic performance of the proposed method in identifying metastatic axillary lymph node in patients with suspected or known breast cancer lesions; correlate the results with pathology as the gold standard. outline: aim 1: participants undergo a breast ultrasound over 15 minutes. aim 2: participants undergo breast ultrasounds over 15 minutes before starting the chemotherapy and/or endocrine therapy, 2 months after start of chemotherapy and/or endocrine therapy, and after the completion of chemotherapy and/or endocrine therapy before surgery. participants may also undergo breast ultrasounds at 2 weeks after start of chemotherapy and/or endocrine therapy and 1 month after start of chemotherapy and/or endocrine therapy . aim 3: patients with suspicious breast masses or known breast cancer who are scheduled for axillary lymph node biopsy undergo ultrasound over 15 minutes at the same visit of the breast mass study.

Eligibility criteria:
inclusion criteria: * aim 1: patient volunteers, ages \>= 18 with suspicious breast masses scheduled for breast biopsy, or at least two weeks or more after breast biopsy * aim 2: patient volunteers, ages \>= 18 who have biopsy proven breast cancer and are going under neoadjuvant chemotherapy and/or endocrine therapy had their baseline mri and/or ultrasound exclusion criteria: * patients with breast implants or any condition that does not allow proper use of ultrasound (us)
guidance model of standardized treatment of antidepressants in bipolar disorder

Conditions: the Use of Antidepressants in Patients With Bipolar Depression

Summary: the bipolar depression patients of 18-55 years old were recruited. at the time of enrollment, the demographic, symptomatic, neuropsychological, neurobiological and genetic data was collected. after the completion of the baseline assessment and examination, the patients were given lithium carbonate or lithium carbonate combined with ssri antidepressant treatment. clinical evaluation was performed at 2 and 8 weeks after treatment, including the therapeutic efficacy and adverse drug reactions, and monitoring of serum lithium concentration. the patients further receive the fmri scans after treatment for 8 weeks. through above work, this study aimed to provide some guidance for the use of antidepressants in patients with bipolar depression.


Eligibility criteria:
inclusion criteria: * age 18-55 years old, bipolar depression exclusion criteria: * other mental illness, serious somatic illnesses, mri contradictions.
biventricular tachycardias outcome trial

Conditions: Biventricular Tachycardias

Summary: this clinical investigation is a device-based open, prospective, multicenter two-arm randomized trial, comparing patients who are treated in the slow vt zone versus patients who are not treated in that zone. the device intended to be used is the ovatiotm crt model 6750 but future generation of sorin group/ ela medical devices may be used provided they are ce marked. ethics committees and health authorities will be informed prior to any use of a newer device if applicable. all patients will have a 3-zone detection configuration programmed. the slow vt zone will be defined by programming the detection parameters as follows: * slow vt detection rate: 100 bpm (or if the resting rate is higher than 80 bpm, we recommend to adjust this parameter to: resting rate + 30 bpm) * vt detection rate: 150 bpm parad+ will be the first choice for svt/st and vt discrimination in the vt zones. the fast vt and vf limits are left to investigator's judgment. therapy on vt, fast vt and vf are also left to the investigator's judgment. patients will be randomized at implant to have the slow vt zone programmed as a monitoring zone (monitoring arm) or to have therapies programmed within the slow vt zone (therapy arm). the randomization table will be generated by sorin group/ela medical.


Eligibility criteria:
inclusion criteria: * patient has been prescribed the implantation or replacement of a crt-icd system accordingly to the relevant currently-approved acc/aha15 (august 2005, appendix §m.10) or esc 16 (update 2005, appendix § m.11) guidelines or any relevant currently-approved local guidelines for the implantation or replacement of crt-icd. * patient has signed a consent form after he/she received the appropriate and mandatory information. exclusion criteria: * clinical history of symptomatic or not symptomatic slow vt; * permanent atrial fibrillation (af); * any contraindication to the implant or replacement of crt-icd; * pt is unable to attend the scheduled f-up visits at the implanting centre; * pt is already included in another ongoing clinical study; * pt is unable to understand the objectives of the itac04 study; * pt refuses to cooperate; * pt is unable or refuses to provide informed consent; * pt is minor (less than 18-year old); * pt has life expectancy of less than 1 year; * pt is pregnant.

Keywords: slow vt, crt-d, atp therapy incidence of slow vts in crt-d patients clinical relevance treatment vts during 2-years follow-up
assessment of the effect of coconut and sunflower seed oil derived isosorbide diseters and colloidial oatmeal

Conditions: Atopic Dermatitis

Summary: the goal of this study is to compare coconut oil and sunflower seed oil derived isosorbide disesters and colloidal oatmeal, and observe their effect on pediatric atopic dermatitis among males and females aged 2-17.


Eligibility criteria:
inclusion criteria: * males and females ages 2-17 years old at the time of consent. * clinical diagnosis of active atopic dermatitis * viga-ad (validated investigator global assessment-atopic dermatitis) score of "mild" (2) or "moderate" (3) at baseline * easi (eczema area and severity index) score of \>/= 5 at baseline exclusion criteria: * individuals who have a known allergy to isosorbide diesters, coconut oil, or sunflower seed oil * individuals who have solely hand and/or foot eczema without evidence of eczema anywhere else on their body. * individuals who have been on topical calcineurin inhibitors or crisaborole to the predetermined areas within two weeks of initiation of participation or unwilling to undergo a washout period. * subjects with an ongoing secondary infection of the skin. * subjects who are on systemic therapy or who need systemic therapy at the discretion of the investigator. systemic therapies include cyclosporine, systemic steroids, methotrexate, and dupilumab. subjects who have been on cyclosporine, systemic steroids, or methotrexate in the month prior to initiation of study intervention or are unwilling to undergo a washout period. subjects who have been on dupilumab in two months prior to initiation of study intervention or are unwilling to undergo a washout period. * subjects with a diagnosis of scabies. * pregnant women * prisoners
the evaluation of a nasal pillows mask for the treatment of obstructive sleep apnea (osa) in nz

Conditions: Obstructive Sleep Apnea

Summary: this investigation is designed to evaluate the performance (leak and comfort) as well as the participant's overall acceptance of the nasal pillows mask amongst obstructive sleep apnea (osa) participants. also to assist in the development process it would be beneficial to get feedback from users on certain aspects of the design. the aim of this investigation is to get feedback on the first impressions (look and feel) from users of nasal pillows pap therapy. a total number of 15 participants who currently use a nasal pillows mask will be recruited for the trial. participants from previous nz trials may be recruited into this trial with their consent. all the participants will be recruited from the fisher \& paykel healthcare database of subjects with osa (ethics reference nty/08/06/064), auckland district health board (adhb) and new zealand respiratory and sleep institute (nzrsi). participants will undergo an overnight polysomnography session at the fisher \& paykel healthcare sleep lab. the participant will use the trial device on their usual continuous or auto positive airway pressure (cpap/apap) setting and device for the duration of the overnight in-lab study.


Eligibility criteria:
inclusion criteria: * adult (18+ years of age) * able to give consent * ahi ≥ 5 on diagnostic night * prescribed a cpap device after successful osa diagnosis * existing nasal pillows mask user exclusion criteria: * inability to give consent * patients who are in a coma or a decreased level of consciousness. * anatomical or physiological conditions making apap therapy inappropriate * commercial drivers who are investigated by new zealand transport agency (nzta) * current diagnosis of co2 retention * pregnant or may think they are pregnant.
sleep deprivation plus paroxetine for treating major depression in elderly individuals

Conditions: Depression

Summary: this study will determine the effectiveness of total sleep deprivation (tsd) for one night plus paroxetine versus either tsd plus placebo or paroxetine alone in inducing rapid symptom resolution of major depression in the elderly.

the clinical response to antidepressant treatment in the elderly is variable and often slow, and difficult to predict reliably before 4-5 weeks of treatment. the delayed onset of antidepressant activity is particularly problematic in the elderly, prolonging the duration of suffering and disability, reducing compliance, and increasing the risk for attempted and completed suicide. this study seeks to develop a method for effective rapid treatment of major depressive episodes in the elderly and to improve early identification of treatment non-responders, by combining sleep deprivation (for one night) and paroxetine as probes of treatment response and treatment resistance. this is an experimental study that is randomized, double-blind, and placebo-controlled. we will recruit 158 elderly depressed patients with current major depressive episodes and randomly assign 36 patients to each of three interventions: 1)tsd + paroxetine; 2)tsd + placebo; and 3)paroxetine alone without tsd). the duration of the experimental phase of the study is 17 days: 3 days for pre-treatment sleep studies and 14 days for initial paroxetine or placebo treatment under double-blind conditions. for information on related studies, please follow these links: http://clinicaltrials.gov/show/nct00177294 http://clinicaltrials.gov/show/nct00178074

Eligibility criteria:
inclusion criteria: * age 60 and older * current episode of unipolar, major depression * hrsd (17 item)score of 15 or higher * folstein mini-mental status exam score of 17 or higher exclusion criteria: * lifetime diagnosis of any psychotic disorder * lifetime diagnosis of bipolar disorder _alcohol or drug abuse within the past 6 months * contraindication to treatment with ssri therapy * history of seizure disorder * baseline apnea/hypopnea index of 20 or higher * hyponatremia

Keywords: depression unipolar depression elderly depression late-life
evaluation of the use of acotec drug-eluting balloon litos ® in below-the-knee arteries to treat critical limb ischemia

Conditions: Peripheral Artery Disease

Summary: the aim of this study is to evaluate the potential advantage in terms of late lumen loss reduction of litos drug-eluting balloon vs standard percutaneous transluminal angioplasty in the treatment of below-the-knee disease in patients with critical limb ischemia.


Eligibility criteria:
inclusion criteria: * age\>18 years * critical limb ischemia (rutherford class 4-6) * angiographic stenosis\>50% or occlusion of at least one tibial vessel of at least 40mm for which an interventional treatment is scheduled exclusion criteria: * need for major amputation known before intervention * allergy to paclitaxel * contraindication for combined antiplatelet treatment * life expectancy \<1 year * hypersensitivity or contraindication to one of the study drugs * lack of consent
s100b as a marker of brain injury of preterm infants

Conditions: Premature Birth; Brain Injuries; Leukomalacia Periventricular; Developmental Disabilities

Summary: the improvement of treatment of preterm neonates improved their survival, however there is still significant portion of preterm infants (specifically very preterm infants) that suffers from brain insults and as a result developmental deficits. the brain injury is a consequence of hypoxic ischemic events, intracranial hemorrhages, as well as, infections and metabolic crisis. the brain injury is a combination of abnormal myelination, axonal damage and neuronal death. although there is reduction in focal brain injury, diffuse brain injury is still abundant. several treatments has been suggested and tested in animal models to prevent the brain insults including glutamate receptor blockers, allopurinol, xenon and different types of stem cells. however, two main obstacles prevent the use of these medication, first the uncertainty of their effect on the developing brain and second the difficulty to time the brain insult. unlike neonatal asphyxia, when the delivery time and clinical signs are used to time and grade the brain injury, in preterm infants there is no real time tool to indicate severity and timing of brain injury. the disability point out a beneficial therapeutic window is a major obstacle in the acute treatment of brain injury in preterm infants. the aim of this study is to try and delineate such therapeutic window by using brain injury biomarkers. s100b and gfap are well recognized biomarkers of brain injury in adults, children and infants. serial measurements of s100b in saliva (every 2 days) and gfap in serum (weekly) will be sampled. a database of the clinical status of the infants will be collected, as well as, head ultra sound weekly and head mri a term age. development will be assessed by at 18 months. two hypotheses are stated: one, increase in the levels of s100b and gfap in their timing will be correlated with the severity of the clinical status, two the duration of increased level of s100b and gfap will be associated with abnormal mri at term findings and abnormal developmental assessment.


Eligibility criteria:
inclusion criteria: - preterm delivery before 30 week gestational age exclusion criteria: * dysmorphic features in initial neurological examination * antenatal brain injury on fetal mri or ultrasound * brain malformation * maternal drug abuse * maternal use of teratogenic medications

Keywords: premature birth brain injuries leukomalacia periventricular s100b protein human glial fibrillary acidic protein magnetic resonance imaging developmental disabilities
behavioral changes among asthmatic children in sohag universty hospital

Conditions: Bronchial Asthma

Summary: asthma is considered the most common chronic childhood disease and mainly affects children resident in urban areas. asthma has been designated a serious public health problem due to the increase in its prevalence over the last two decades and the associated high health service costs in admissions and hospitalizations the cause of asthma is not yet completely understood, and there is no consensus about its etiology. a vast body of research emphasizes the role of genetic and environmental factors in the appearance of asthma, and a great deal of interest has recently emerged concerning the relationship between psychosocial factors and asthma morbidity behavioural problems in children are generally described as "internalizing", which includes "anxiety, depressive, and somatic symptoms" or "externalizing", which includes "oppositional, hyperactive conduct". both internalizing and externalizing problems can be experienced by healthy children with abnormal and "borderline" personality disorder, the latter referring to a mental illness marked by an ongoing pattern of varying moods, self-image, and behaviour


Eligibility criteria:
inclusion criteria: children aged 4-12 years confirmed diagnosed as asthma exclusion criteria: children below age of 4 years and aboveage of 12 years . diagnosed with any other chronic medical conditions (e.g., cardiac , liver , renal and other chronic chest diseases) . patient with cerebral palsy.
the effect of ac-134 in chronic kidney diseases

Conditions: Nephrology

Summary: the objective is to explore the effects of adding ac-134 on renal function, proteinuria, uremic toxins, and metabolism-related markers in chronic kidney disease.

chronic kidney disease (ckd) management primarily focuses on addressing associated complications such as hypertension, diabetes mellitus, cardiovascular disease, and proteinuria. in addition to standard therapies, reducing the accumulation of toxins, particularly gut-derived uremic toxins like indoxyl sulfate (is) and p-cresol sulfate (pcs), may help alleviate uremia symptoms. this study assesses the impact of oral ac-134 capsules containing activated charcoal adsorbent on ckd patients. the assessment will include evaluating changes in renal function, proteinuria, uremic toxins, and metabolism-related markers.

Eligibility criteria:
inclusion criteria: * aged 20-90 years. * diagnosed with stage 3-5 chronic kidney disease, excluding dialysis patients. * signed informed consent is required before enrollment. exclusion criteria: * use of other brand-activated charcoal supplements during the study period. * pregnant or lactating women. * patients who have undergone kidney transplantation. * obstructive nephropathy within the past month. * acute kidney injury within the past three months. * gastrointestinal bleeding or severe constipation within the past three months. * patients with active malignancy within the past two years. * severe cardiovascular diseases such as congestive heart failure new york class iii-iv or cerebrovascular disease * severe liver disease, such as liver cirrhosis with ascites. * active infectious disease

Keywords: chronic kidney diseases activated charcoal